Медицинская библиотека · Journal of voice : official journal of the Voice Foundation · 2018

Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study.

Di Stadio Arianna, Bernitsas Evanthia, Restivo Domenico Antonio, Alfonsi Enrico, Marchese-Ragona Rosario

Клинический случайСтатьяПеревод в очереди

Аннотация

OBJECTIVES

This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.

MATERIALS AND

METHODS

This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.

RESULTS

None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.

CONCLUSIONS

Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

Для цитирования: Di Stadio Arianna, Bernitsas Evanthia, Restivo Domenico Antonio, Alfonsi Enrico, Marchese-Ragona Rosario. Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study.. Journal of voice : official journal of the Voice Foundation. 2018. DOI: 10.1016/j.jvoice.2018.01.002.

Предметные рубрики MeSH

Acetylcholine Release Inhibitors Adult Botulinum Toxins, Type A Dysphonia Female Humans Injections, Intramuscular Larynx Male Middle Aged Multiple Sclerosis, Relapsing-Remitting Pilot Projects Recovery of Function Time Factors Treatment Outcome Voice

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.